Related references
Note: Only part of the references are listed.Low serum potassium levels and risk of type 2 diabetes: the Toranomon Hospital Health Management Center Study 1 (TOPICS 1)
Y. Heianza et al.
DIABETOLOGIA (2011)
Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease
Stergios A. Polyzos et al.
JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (2011)
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms.
Faiez Zannad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Randomized Study of the Beneficial Effects of Aldosterone Antagonism on LV Function, Structure, and Fibrosis Markers in Metabolic Syndrome
Wojciech Kosmala et al.
JACC-CARDIOVASCULAR IMAGING (2011)
Effect of eplerenone versus spironolactone on cortisol and hemoglobin A1c levels in patients with chronic heart failure
Masayuki Yamaji et al.
AMERICAN HEART JOURNAL (2010)
Rationale and design of the Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure (EMPHASIS-HF)
Faiez Zannad et al.
EUROPEAN JOURNAL OF HEART FAILURE (2010)
Aldosterone Production and Insulin Resistance in Healthy Adults
Rajesh Garg et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events
John J. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Predictors of Development in Patients With Chronic Heart Failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Program
David Preiss et al.
DIABETES CARE (2009)
Alanine Aminotransferase, γ-Glutamyltransferase, and Incident Diabetes
Abigail Fraser et al.
DIABETES CARE (2009)
Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles
K. Swaminathan et al.
DIABETOLOGIA (2008)
Diabetes, left ventricular systolic dysfunction, and chronic heart failure
Michael R. MacDonald et al.
EUROPEAN HEART JOURNAL (2008)
Predictors of new-onset diabetes mellitus in hypertensive patients:: the VALUE trial
T. A. Aksnes et al.
JOURNAL OF HUMAN HYPERTENSION (2008)
Predicting the 20-year diabetes incidence rate
Rachel Dankner et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2007)
Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)
Christian Torp-Pedersen et al.
HEART (2007)
Incident diabetes in clinical trials of anti hypertensive drugs: a network meta-analysis
William J. Elliott et al.
LANCET (2007)
Animal and human tissue Na,K-ATPase in obesity and diabetes: A new proposed enzyme regulation
Silvia Iannello et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2007)
The effect of spironolactone on circulating adipocytokines in patients with type 2 diabetes mellitus complicated by diabetic nephropathy
Sachiko Matsumoto et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2006)
Insulin sensitivity in patients with primary aldosteronism: A follow-up study
Cristiana Catena et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure
S Yusuf et al.
CIRCULATION (2005)
Spironolactone impairs endothelial function and heart rate variability in patients with Type 2 diabetes
JI Davies et al.
DIABETOLOGIA (2004)
Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the West of Scotland Coronary Prevention Study
N Sattar et al.
DIABETES (2004)
Functional capacity impairment in patients with coronary artery disease: Prevalence, risk factors and prognosis
A Tenenbaum et al.
CARDIOLOGY (2003)
Share Paper
